Predicine is a molecular insights company that is committed to advancing biomarker-driven precision medicine. Predicine has developed a breakthrough cfRNA and cfDNA liquid biopsy technology for non-invasive cancer profiling, disease monitoring and assessing minimal residual disease. Through its CLIA and/or CAP facilities in US and China, Predicine partners with leading biopharma companies and hospitals to support global clinical trials and personalized cancer therapy.
Our next-generation liquid biopsy technology built to detect tumor mutation burden (TMB) for immuno-oncology, DNA damage repair (DDR) for PARP inhibitors, AR-V7 RNA gene expression for AR inhibitors using ctDNA or ctRNA input from blood or urine samples. Our liquid biopsy assays range from 21 to 600 gene targets designed to enable and accelerate biomarker-driven global clinical trials.
"strong scientific technology and knowledge . delivery on time. response promptly"
Predicine Inc has not received any endorsements.